Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). / Kindler, Thomas; Breitenbuecher, Frank; Kasper, Stefan; Estey, Eli; Giles, Francis; Feldman, Eric; Ehninger, Gerhard; Schiller, Gary; Klimek, Virginia; Nimer, Stephen D; Gratwohl, Alois; Choudhary, Chuna Ram; Mueller-Tidow, Constan; Serve, Hubert; Gschaidmeier, Harald; Cohen, Pamela S; Huber, Christoph; Fischer, Thomas.

In: Blood, Vol. 105, No. 1, 2005, p. 335-40.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kindler, T, Breitenbuecher, F, Kasper, S, Estey, E, Giles, F, Feldman, E, Ehninger, G, Schiller, G, Klimek, V, Nimer, SD, Gratwohl, A, Choudhary, CR, Mueller-Tidow, C, Serve, H, Gschaidmeier, H, Cohen, PS, Huber, C & Fischer, T 2005, 'Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)', Blood, vol. 105, no. 1, pp. 335-40. https://doi.org/10.1182/blood-2004-02-0660

APA

Kindler, T., Breitenbuecher, F., Kasper, S., Estey, E., Giles, F., Feldman, E., ... Fischer, T. (2005). Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood, 105(1), 335-40. https://doi.org/10.1182/blood-2004-02-0660

Vancouver

Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E et al. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood. 2005;105(1):335-40. https://doi.org/10.1182/blood-2004-02-0660

Author

Kindler, Thomas ; Breitenbuecher, Frank ; Kasper, Stefan ; Estey, Eli ; Giles, Francis ; Feldman, Eric ; Ehninger, Gerhard ; Schiller, Gary ; Klimek, Virginia ; Nimer, Stephen D ; Gratwohl, Alois ; Choudhary, Chuna Ram ; Mueller-Tidow, Constan ; Serve, Hubert ; Gschaidmeier, Harald ; Cohen, Pamela S ; Huber, Christoph ; Fischer, Thomas. / Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). In: Blood. 2005 ; Vol. 105, No. 1. pp. 335-40.

Bibtex

@article{09c950d8dc9a46aaa4f784d912cd78ea,
title = "Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)",
abstract = "Fms-like tyrosine kinase 3 (FLT3) receptor mutations as internal tandem duplication (ITD) or within the kinase domain are detected in up to 35{\%} of patients with acute myeloid leukemia (AML). N-benzoyl staurosporine (PKC412), a highly effective inhibitor of mutated FLT3 receptors, has significant antileukemic efficacy in patients with FLT3-mutated AML. Mutation screening of FLT3 exon 20 in AML patients (n = 110) revealed 2 patients with a novel mutation (Y842C) within the highly conserved activation loop of FLT3. FLT3-Y842C-transfected 32D cells showed constitutive FLT3 tyrosine phosphorylation and interleukin 3 (IL-3)-independent growth. Treatment with PKC412 led to inhibition of proliferation and apoptotic cell death. Primary AML blasts bearing FLT3-Y842C mutations showed constitutive FLT3 and signal transducer and activator of transcription 5 (STAT-5) tyrosine phosphorylation. Ex vivo PKC412 treatment of primary blasts resulted in suppression of constitutive FLT3 and STAT-5 activation and apoptotic cell death. Inspection of the FLT3 structure revealed that Y842 is the key residue in regulating the switch from the closed to the open (= active) conformation of the FLT3 activation loop. Overall, our data suggest that mutations at Y842 represent a significant new activating mutation in AML blasts. Since FLT3 tyrosine kinase inhibitors (TKIs) such as PKC412 are currently being investigated in clinical trials in AML, extended sequence analysis of FLT3 may be helpful in defining the spectrum of TKI-sensitive FLT3 mutations in AML.",
author = "Thomas Kindler and Frank Breitenbuecher and Stefan Kasper and Eli Estey and Francis Giles and Eric Feldman and Gerhard Ehninger and Gary Schiller and Virginia Klimek and Nimer, {Stephen D} and Alois Gratwohl and Choudhary, {Chuna Ram} and Constan Mueller-Tidow and Hubert Serve and Harald Gschaidmeier and Cohen, {Pamela S} and Christoph Huber and Thomas Fischer",
year = "2005",
doi = "10.1182/blood-2004-02-0660",
language = "English",
volume = "105",
pages = "335--40",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

RIS

TY - JOUR

T1 - Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)

AU - Kindler, Thomas

AU - Breitenbuecher, Frank

AU - Kasper, Stefan

AU - Estey, Eli

AU - Giles, Francis

AU - Feldman, Eric

AU - Ehninger, Gerhard

AU - Schiller, Gary

AU - Klimek, Virginia

AU - Nimer, Stephen D

AU - Gratwohl, Alois

AU - Choudhary, Chuna Ram

AU - Mueller-Tidow, Constan

AU - Serve, Hubert

AU - Gschaidmeier, Harald

AU - Cohen, Pamela S

AU - Huber, Christoph

AU - Fischer, Thomas

PY - 2005

Y1 - 2005

N2 - Fms-like tyrosine kinase 3 (FLT3) receptor mutations as internal tandem duplication (ITD) or within the kinase domain are detected in up to 35% of patients with acute myeloid leukemia (AML). N-benzoyl staurosporine (PKC412), a highly effective inhibitor of mutated FLT3 receptors, has significant antileukemic efficacy in patients with FLT3-mutated AML. Mutation screening of FLT3 exon 20 in AML patients (n = 110) revealed 2 patients with a novel mutation (Y842C) within the highly conserved activation loop of FLT3. FLT3-Y842C-transfected 32D cells showed constitutive FLT3 tyrosine phosphorylation and interleukin 3 (IL-3)-independent growth. Treatment with PKC412 led to inhibition of proliferation and apoptotic cell death. Primary AML blasts bearing FLT3-Y842C mutations showed constitutive FLT3 and signal transducer and activator of transcription 5 (STAT-5) tyrosine phosphorylation. Ex vivo PKC412 treatment of primary blasts resulted in suppression of constitutive FLT3 and STAT-5 activation and apoptotic cell death. Inspection of the FLT3 structure revealed that Y842 is the key residue in regulating the switch from the closed to the open (= active) conformation of the FLT3 activation loop. Overall, our data suggest that mutations at Y842 represent a significant new activating mutation in AML blasts. Since FLT3 tyrosine kinase inhibitors (TKIs) such as PKC412 are currently being investigated in clinical trials in AML, extended sequence analysis of FLT3 may be helpful in defining the spectrum of TKI-sensitive FLT3 mutations in AML.

AB - Fms-like tyrosine kinase 3 (FLT3) receptor mutations as internal tandem duplication (ITD) or within the kinase domain are detected in up to 35% of patients with acute myeloid leukemia (AML). N-benzoyl staurosporine (PKC412), a highly effective inhibitor of mutated FLT3 receptors, has significant antileukemic efficacy in patients with FLT3-mutated AML. Mutation screening of FLT3 exon 20 in AML patients (n = 110) revealed 2 patients with a novel mutation (Y842C) within the highly conserved activation loop of FLT3. FLT3-Y842C-transfected 32D cells showed constitutive FLT3 tyrosine phosphorylation and interleukin 3 (IL-3)-independent growth. Treatment with PKC412 led to inhibition of proliferation and apoptotic cell death. Primary AML blasts bearing FLT3-Y842C mutations showed constitutive FLT3 and signal transducer and activator of transcription 5 (STAT-5) tyrosine phosphorylation. Ex vivo PKC412 treatment of primary blasts resulted in suppression of constitutive FLT3 and STAT-5 activation and apoptotic cell death. Inspection of the FLT3 structure revealed that Y842 is the key residue in regulating the switch from the closed to the open (= active) conformation of the FLT3 activation loop. Overall, our data suggest that mutations at Y842 represent a significant new activating mutation in AML blasts. Since FLT3 tyrosine kinase inhibitors (TKIs) such as PKC412 are currently being investigated in clinical trials in AML, extended sequence analysis of FLT3 may be helpful in defining the spectrum of TKI-sensitive FLT3 mutations in AML.

U2 - 10.1182/blood-2004-02-0660

DO - 10.1182/blood-2004-02-0660

M3 - Journal article

C2 - 15345593

VL - 105

SP - 335

EP - 340

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -

ID: 40291570